|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases response to substance decreases response to substance |
ISO |
APEX1 protein mutant form results in increased susceptibility to Dacarbazine APEX1 protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:16373707 PMID:19470598 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression |
ISO |
Dacarbazine results in increased expression of BIRC5 protein |
CTD |
PMID:15577328 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
Dacarbazine results in increased cleavage of and results in increased activity of CASP3 protein; TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP3 protein] |
CTD |
PMID:17410615 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
Dacarbazine results in increased cleavage of and results in increased activity of CASP8 protein; TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP8 protein] |
CTD |
PMID:17410615 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
[Dacarbazine co-treated with IFNA1 protein] results in increased expression of CD38 protein; [Dacarbazine co-treated with IFNA2 protein] results in increased expression of CD38 protein; Dacarbazine promotes the reaction [IFNA1 protein results in increased expression of CD38 protein] |
CTD |
PMID:11583285 PMID:14669796 PMID:16078447 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd69 |
Cd69 molecule |
multiple interactions |
ISO |
[Dacarbazine co-treated with IFNA2 protein] results in increased expression of CD69 protein; [Dacarbazine co-treated with Isotretinoin] affects the reaction [IFNA2 protein results in increased expression of CD69 protein]; Dacarbazine affects the reaction [IFNA2 protein results in increased expression of CD69 protein] |
CTD |
PMID:14669796 PMID:17973783 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Clu |
clusterin |
affects response to substance |
ISO |
CLU protein affects the susceptibility to Dacarbazine |
CTD |
PMID:15955107 |
|
NCBI chr15:42,626,612...42,665,858
Ensembl chr15:42,640,146...42,665,857
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases metabolic processing multiple interactions |
ISO |
CYP1A1 protein results in increased metabolism of Dacarbazine metabolite O(6)-benzylguanine inhibits the reaction [CYP1A1 protein results in increased metabolism of Dacarbazine metabolite] |
CTD |
PMID:11751525 |
|
NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing multiple interactions |
ISO |
CYP1A2 protein results in increased metabolism of Dacarbazine metabolite O(6)-benzylguanine inhibits the reaction [CYP1A2 protein results in increased metabolism of Dacarbazine metabolite] |
CTD |
PMID:11751525 |
|
NCBI chr 8:62,451,360...62,458,244
Ensembl chr 8:62,451,329...62,458,301
|
|
G |
Epo |
erythropoietin |
decreases response to substance |
ISO |
EPO protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15743794 |
|
NCBI chr12:22,274,828...22,278,268
Ensembl chr12:22,274,828...22,278,266
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Dacarbazine co-treated with Dinitrochlorobenzene] results in increased expression of IFNG mRNA |
CTD |
PMID:12202904 |
|
NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Dacarbazine co-treated with Dinitrochlorobenzene] results in increased expression of IL6 mRNA |
CTD |
PMID:12202904 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Irf1 |
interferon regulatory factor 1 |
increases expression multiple interactions |
ISO |
Dacarbazine results in increased expression of IRF1 mRNA Isotretinoin promotes the reaction [Dacarbazine results in increased expression of IRF1 mRNA] |
CTD |
PMID:17973783 |
|
NCBI chr10:39,109,530...39,116,532
Ensembl chr10:39,109,522...39,116,531
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
decreases response to substance |
ISO |
MAP3K1 protein modified form results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15123733 |
|
NCBI chr 2:43,329,516...43,393,203
Ensembl chr 2:43,329,516...43,393,207
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
decreases response to substance |
ISO |
MAPK1 protein modified form results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15123733 |
|
NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
decreases response to substance |
ISO |
MAPK3 protein modified form results in decreased susceptibility to Dacarbazine |
CTD |
PMID:15123733 |
|
NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
decreases response to substance |
ISO |
MCL1 protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:12787138 |
|
NCBI chr 2:197,786,212...197,788,992
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases activity decreases response to substance increases response to substance affects response to substance decreases expression |
ISO |
Dacarbazine results in decreased activity of MGMT protein MGMT protein results in decreased susceptibility to Dacarbazine MGMT gene mutant form results in increased susceptibility to Dacarbazine MGMT protein affects the susceptibility to Dacarbazine Dacarbazine results in decreased expression of MGMT protein |
CTD |
PMID:10751609 PMID:11023546 PMID:12170182 PMID:12494480 PMID:14562026 PMID:15010317 PMID:15870882 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
decreases response to substance |
ISO |
SLC2A1 protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:17520257 |
|
NCBI chr 5:138,154,677...138,182,897
Ensembl chr 5:138,154,673...138,182,897
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[Dacarbazine co-treated with Dinitrochlorobenzene] results in increased expression of TNF mRNA |
CTD |
PMID:12202904 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
multiple interactions |
ISO |
TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP3 protein]; TNFSF10 protein promotes the reaction [Dacarbazine results in increased cleavage of and results in increased activity of CASP8 protein] |
CTD |
PMID:17410615 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases secretion increases expression decreases response to substance |
ISO |
Dacarbazine results in increased secretion of VEGFA protein Dacarbazine results in increased expression of VEGFA mRNA; Dacarbazine results in increased expression of VEGFA protein VEGFA protein results in decreased susceptibility to Dacarbazine |
CTD |
PMID:12939465 PMID:15026559 PMID:15123733 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases activity |
ISO |
Diminazene results in increased activity of ACE2 protein |
CTD |
PMID:21859683 |
|
NCBI chr X:32,050,734...32,095,860
Ensembl chr X:32,049,931...32,096,016
|
|
G |
Asic5 |
acid sensing ion channel subunit family member 5 |
decreases activity |
ISO EXP |
Diminazene results in decreased activity of ASIC5 protein |
CTD |
PMID:21828194 |
|
NCBI chr 2:180,935,392...180,964,365
Ensembl chr 2:180,936,688...180,964,365
|
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects response to substance |
ISO |
ABCC2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
affects response to substance |
ISO |
ABCG5 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:7,935,771...7,961,207
Ensembl chr 6:7,935,771...7,961,207
|
|
G |
Agr3 |
anterior gradient 3, protein disulphide isomerase family member |
affects response to substance |
ISO |
AGR3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:55,371,738...55,424,233
Ensembl chr 6:55,371,738...55,424,674
|
|
G |
Agt |
angiotensinogen |
decreases response to substance |
ISO |
AGT protein mutant form results in decreased susceptibility to temozolomide; AGT protein results in decreased susceptibility to temozolomide |
CTD |
PMID:11034089 |
|
NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B |
affects response to substance |
ISO |
AKR1B1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:61,706,866...61,720,959
Ensembl chr 4:61,706,864...61,720,956
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
AKT1 protein inhibits the reaction [temozolomide results in increased phosphorylation of and results in decreased activity of CDC25C protein]; AKT1 protein inhibits the reaction [temozolomide results in increased phosphorylation of and results in decreased activity of CDK1 protein]; AKT1 protein inhibits the reaction [temozolomide results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:15930307 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh1a3 |
aldehyde dehydrogenase 1 family, member A3 |
affects response to substance |
ISO |
ALDH1A3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:127,302,920...127,337,828
Ensembl chr 1:127,301,128...127,337,882
|
|
G |
Ank2 |
ankyrin 2 |
affects response to substance |
ISO |
ANK2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:231,224,643...231,522,655
Ensembl chr 2:231,226,949...231,648,122
|
|
G |
Ankrd1 |
ankyrin repeat domain 1 |
affects response to substance |
ISO |
ANKRD1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:254,726,985...254,745,673
Ensembl chr 1:254,726,969...254,735,548
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
affects response to substance |
ISO |
AP1S2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr X:32,329,883...32,376,301
Ensembl chr X:32,329,598...32,355,307
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
affects response to substance |
ISO |
APC mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr18:27,011,710...27,106,323
Ensembl chr18:27,047,382...27,105,531
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
decreases response to substance increases response to substance |
ISO |
APEX1 protein results in decreased susceptibility to temozolomide APEX1 protein mutant form results in increased susceptibility to temozolomide |
CTD |
PMID:12231548 PMID:16243814 PMID:19470598 |
|
NCBI chr15:27,849,943...27,852,083
Ensembl chr15:27,849,979...27,852,082
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
affects response to substance |
ISO |
ARF1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Arrdc2 |
arrestin domain containing 2 |
affects response to substance |
ISO |
ARRDC2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:20,352,480...20,356,612
Ensembl chr16:20,352,480...20,356,612
|
|
G |
Atm |
ATM serine/threonine kinase |
multiple interactions increases phosphorylation |
ISO |
[temozolomide co-treated with resveratrol] results in increased phosphorylation of ATM protein temozolomide results in increased phosphorylation of ATM protein |
CTD |
PMID:23522185 |
|
NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
|
|
G |
Atr |
ATR serine/threonine kinase |
multiple interactions |
ISO |
[4-cyclohexylmethoxy-5-nitrosopyrimidine-2,6-diamine results in decreased activity of ATR] which results in increased susceptibility to temozolomide |
CTD |
PMID:21730979 |
|
NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
|
|
G |
B4galnt2 |
beta-1,4-N-acetyl-galactosaminyl transferase 2 |
multiple interactions increases mutagenesis |
ISO |
MSH2 gene mutant form promotes the reaction [temozolomide results in increased mutagenesis of B4GALNT2] |
CTD |
PMID:20025921 |
|
NCBI chr10:83,677,768...83,701,487
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
Temozolomide analog results in increased expression of BAX protein; Temozolomide results in increased expression of BAX mRNA; Temozolomide results in increased expression of BAX protein [Verapamil co-treated with Temozolomide] results in increased expression of BAX mRNA; Temozolomide promotes the reaction [Verapamil results in increased expression of BAX protein] [temozolomide co-treated with O(6)-benzylguanine] results in increased expression of BAX protein; TRP53 protein affects the reaction [[temozolomide co-treated with O(6)-benzylguanine] results in increased expression of BAX protein] |
CTD |
PMID:19363609 PMID:20980775 PMID:30003979 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO |
[temozolomide co-treated with O(6)-benzylguanine] results in decreased expression of BCL2 protein; TRP53 protein mutant form inhibits the reaction [[temozolomide co-treated with O(6)-benzylguanine] results in decreased expression of BCL2 protein] [Temozolomide co-treated with Verapamil] results in decreased expression of BCL2 mRNA; [Temozolomide co-treated with Verapamil] results in decreased expression of BCL2 protein; Resveratrol promotes the reaction [Temozolomide results in decreased expression of BCL2 protein] temozolomide analog results in decreased expression of BCL2 protein; temozolomide results in decreased expression of BCL2 protein |
CTD |
PMID:19363609 PMID:20980775 PMID:22530672 PMID:30003979 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
ISO |
MGMT protein affects the reaction [BCL2L1 protein affects the susceptibility to temozolomide] |
CTD |
PMID:16405512 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bcl2l11 |
BCL2 like 11 |
multiple interactions increases expression |
ISO |
BCL2L11 mutant form inhibits the reaction [temozolomide results in increased cleavage of CASP9 protein]; pyrazolanthrone inhibits the reaction [temozolomide results in increased expression of BCL2L11 mRNA] temozolomide results in increased expression of BCL2L11 mRNA; temozolomide results in increased expression of BCL2L11 protein |
CTD |
PMID:26418950 |
|
NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
ISO |
temozolomide results in increased expression of BECN1 protein Thalidomide promotes the reaction [temozolomide results in increased expression of BECN1 protein] |
CTD |
PMID:19567134 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression multiple interactions |
ISO |
temozolomide results in decreased expression of BIRC5 protein XAF1 protein promotes the reaction [temozolomide results in decreased expression of BIRC5 protein] |
CTD |
PMID:28122345 |
|
NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
|
|
G |
Bmp5 |
bone morphogenetic protein 5 |
affects response to substance |
ISO |
BMP5 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 8:82,669,466...82,950,273
Ensembl chr 8:82,878,941...82,950,273
|
|
G |
Brca2 |
BRCA2, DNA repair associated |
decreases response to substance |
ISO |
BRCA2 protein results in decreased susceptibility to temozolomide |
CTD |
PMID:20028873 |
|
NCBI chr12:503,660...544,754
Ensembl chr12:504,007...544,748
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
affects response to substance |
ISO |
CADM1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 8:51,858,906...52,200,591
Ensembl chr 8:52,127,399...52,189,722
|
|
G |
Casp12 |
caspase 12 |
increases expression multiple interactions |
ISO |
temozolomide results in increased expression of CASP12 protein [temozolomide co-treated with Quercetin] results in increased expression of CASP12 protein |
CTD |
PMID:24126416 |
|
NCBI chr 8:2,658,892...2,686,160
Ensembl chr 8:2,659,865...2,686,160
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases activity increases cleavage increases expression |
ISO |
[Pyrimethamine co-treated with Temozolomide] results in increased cleavage of CASP3 protein; [Quercetin co-treated with Temozolomide] results in increased activity of CASP3 protein; [Temozolomide co-treated with Quercetin] results in increased activity of CASP3 protein temozolomide analog results in increased activity of CASP3 protein; temozolomide results in increased activity of CASP3 protein temozolomide results in increased cleavage of CASP3 protein temozolomide results in increased expression of CASP3 |
CTD |
PMID:19363609 PMID:19435820 PMID:20654599 PMID:22231932 PMID:24126416 PMID:26418950 PMID:26911376 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
temozolomide results in increased activity of CASP7 protein |
CTD |
PMID:26911376 |
|
NCBI chr 1:277,190,557...277,242,779
Ensembl chr 1:277,190,964...277,242,774
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases cleavage |
ISO |
[eckol co-treated with temozolomide] results in increased cleavage of CASP8 protein temozolomide results in increased cleavage of CASP8 protein |
CTD |
PMID:21514314 PMID:26418950 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
[Temozolomide co-treated with Quercetin] results in increased activity of CASP9 protein; BCL2L11 mutant form inhibits the reaction [Temozolomide results in increased cleavage of CASP9 protein] temozolomide results in increased cleavage of CASP9 protein |
CTD |
PMID:24126416 PMID:26418950 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
affects response to substance decreases expression affects activity |
ISO |
CCL2 mRNA affects the susceptibility to temozolomide temozolomide results in decreased expression of CCL2 protein temozolomide affects the activity of CCL2 protein |
CTD |
PMID:16365179 PMID:17522861 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccn4 |
cellular communication network factor 4 |
affects response to substance |
ISO |
CCN4 mRNA affects the susceptibility to Temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:107,695,227...107,723,759
Ensembl chr 7:107,695,215...107,723,772
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[resveratrol co-treated with temozolomide] results in increased expression of CCNB1 protein |
CTD |
PMID:23522185 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnd1 |
cyclin D1 |
decreases phosphorylation multiple interactions affects response to substance |
ISO |
temozolomide results in decreased phosphorylation of CCND1 protein [temozolomide co-treated with resveratrol] results in decreased expression of CCND1 protein CCND1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:15930307 PMID:16365179 PMID:23522185 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
affects response to substance |
ISO |
CD44 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd59 |
CD59 molecule |
decreases lipidation |
EXP |
temozolomide results in decreased lipidation of CD59 protein |
CTD |
PMID:27931811 |
|
NCBI chr 3:94,010,481...94,028,660
Ensembl chr 3:94,010,475...94,028,621
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
AKT1 protein inhibits the reaction [temozolomide results in increased phosphorylation of and results in decreased activity of CDC25C protein]; temozolomide results in increased phosphorylation of and results in decreased activity of CDC25C protein |
CTD |
PMID:15930307 |
|
NCBI chr18:27,528,768...27,550,316
Ensembl chr18:27,528,354...27,550,224
|
|
G |
Cdh13 |
cadherin 13 |
affects response to substance |
ISO |
CDH13 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:50,848,793...51,971,618
Ensembl chr19:50,848,736...51,972,103
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions affects phosphorylation |
ISO |
[temozolomide co-treated with resveratrol] results in decreased phosphorylation of CDK1 protein; AKT1 protein inhibits the reaction [temozolomide results in increased phosphorylation of and results in decreased activity of CDK1 protein]; temozolomide results in increased phosphorylation of and results in decreased activity of CDK1 protein temozolomide affects the phosphorylation of CDK1 protein |
CTD |
PMID:15930307 PMID:23522185 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
[temozolomide co-treated with O(6)-benzylguanine] results in increased expression of CDKN1A protein; TRP53 protein affects the reaction [[temozolomide co-treated with O(6)-benzylguanine] results in increased expression of CDKN1A protein] [temozolomide co-treated with O(6)-benzylguanine] affects the localization of CDKN1A protein; [temozolomide co-treated with O(6)-benzylguanine] results in increased expression of CDKN1A protein temozolomide results in increased expression of CDKN1A protein |
CTD |
PMID:16193384 PMID:20980775 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[temozolomide co-treated with O(6)-benzylguanine] results in decreased expression of CDKN1B protein |
CTD |
PMID:20980775 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
affects response to substance |
ISO |
CDKN1C mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:216,661,067...216,663,791
Ensembl chr 1:216,661,080...216,663,721
|
|
G |
Chd2 |
chromodomain helicase DNA binding protein 2 |
affects response to substance |
ISO |
CHD2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:134,757,934...134,873,053
Ensembl chr 1:134,757,934...134,871,167
|
|
G |
Chek1 |
checkpoint kinase 1 |
increases phosphorylation multiple interactions |
ISO |
temozolomide results in increased phosphorylation of CHEK1 protein; temozolomide results in increased phosphorylation of CHK1 protein XAF1 protein promotes the reaction [temozolomide results in increased phosphorylation of CHK1 protein] |
CTD |
PMID:15930307 PMID:28122345 |
|
NCBI chr 8:39,181,162...39,201,588
Ensembl chr 8:39,181,163...39,243,882
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions increases phosphorylation |
ISO |
[temozolomide co-treated with resveratrol] results in increased phosphorylation of CHEK2 protein; AKT1 protein inhibits the reaction [temozolomide results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:15930307 PMID:23522185 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
affects response to substance |
ISO |
COL1A1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:82,745,801...82,762,790
Ensembl chr10:82,745,801...82,762,789
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
affects response to substance increases expression |
ISO |
COX4I1 protein affects the susceptibility to temozolomide temozolomide results in increased expression of COX4I1 protein |
CTD |
PMID:20870728 |
|
NCBI chr19:54,245,958...54,252,198
Ensembl chr19:54,245,950...54,252,225
|
|
G |
Cox4i2 |
cytochrome c oxidase subunit 4i2 |
decreases expression |
ISO |
temozolomide results in decreased expression of COX4I2 protein |
CTD |
PMID:20870728 |
|
NCBI chr 3:148,234,546...148,245,424
Ensembl chr 3:148,234,193...148,245,416
|
|
G |
Csf2 |
colony stimulating factor 2 |
affects response to substance |
ISO |
CSF2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csgalnact1 |
chondroitin sulfate N-acetylgalactosaminyltransferase 1 |
affects response to substance |
ISO |
CSGALNACT1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:22,704,318...23,075,071
Ensembl chr16:22,979,444...23,074,798
|
|
G |
Csrp3 |
cysteine and glycine rich protein 3 |
affects response to substance |
ISO |
CSRP3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:104,147,205...104,166,389
Ensembl chr 1:104,147,206...104,166,367
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
affects response to substance |
ISO |
CXCL1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr14:18,743,678...18,745,457
Ensembl chr14:18,743,685...18,745,457
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
affects response to substance decreases secretion |
ISO |
CXCL2 mRNA affects the susceptibility to temozolomide temozolomide results in decreased secretion of CXCL2 protein |
CTD |
PMID:16365179 PMID:21509778 |
|
NCBI chr14:18,731,346...18,733,391
Ensembl chr14:18,731,378...18,733,391
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
affects response to substance |
ISO |
CXCL1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Dct |
dopachrome tautomerase |
decreases response to substance |
ISO |
DCT protein results in decreased susceptibility to temozolomide |
CTD |
PMID:15897911 |
|
NCBI chr15:103,208,174...103,245,033
Ensembl chr15:103,208,258...103,244,494
|
|
G |
Def6 |
DEF6 guanine nucleotide exchange factor |
affects response to substance |
ISO |
DEF6 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr20:7,788,120...7,809,011
Ensembl chr20:7,788,084...7,809,560
|
|
G |
Dhrs3 |
dehydrogenase/reductase 3 |
affects response to substance |
ISO |
DHRS3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:162,809,090...162,843,385
Ensembl chr 5:162,808,646...162,843,383
|
|
G |
Dhx37 |
DEAH-box helicase 37 |
affects response to substance |
ISO |
DHX37 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr12:36,594,058...36,614,165
Ensembl chr12:36,594,047...36,614,210
|
|
G |
Dmrtc2 |
DMRT-like family C2 |
affects response to substance |
ISO |
DMRTC2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:81,734,256...81,741,419
Ensembl chr 1:81,736,335...81,741,345
|
|
G |
Dyrk1b |
dual specificity tyrosine phosphorylation regulated kinase 1B |
affects response to substance |
ISO |
DYRK1B mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:85,112,819...85,120,840
Ensembl chr 1:85,112,247...85,120,839
|
|
G |
Ednra |
endothelin receptor type A |
affects response to substance |
ISO |
EDNRA mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:33,928,356...33,991,703
Ensembl chr19:33,928,356...33,991,703
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
affects response to substance |
ISO |
EIF4A2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr11:81,373,047...81,379,680
Ensembl chr11:81,373,048...81,379,871
|
|
G |
Elmo1 |
engulfment and cell motility 1 |
affects response to substance |
ISO |
ELMO1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr17:46,352,102...46,888,788
Ensembl chr17:46,353,330...46,794,845
|
|
G |
Etv1 |
ETS variant transcription factor 1 |
affects response to substance |
ISO |
ETV1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:58,467,215...58,558,640
Ensembl chr 6:58,467,254...58,558,631
|
|
G |
Extl1 |
exostosin-like glycosyltransferase 1 |
affects response to substance |
ISO |
EXTL1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:152,573,755...152,588,956
Ensembl chr 5:152,573,758...152,589,719
|
|
G |
Fancc |
FA complementation group C |
affects response to substance |
ISO |
FANCC mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr17:826,512...955,703
Ensembl chr17:833,509...955,615
|
|
G |
Fancd2 |
FA complementation group D2 |
increases ubiquitination affects localization |
ISO |
temozolomide results in increased ubiquitination of FANCD2 protein temozolomide affects the localization of FANCD2 protein |
CTD |
PMID:17221219 |
|
NCBI chr 4:145,489,869...145,551,479
Ensembl chr 4:145,489,869...145,551,479
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
pyrazolanthrone affects the reaction [temozolomide results in increased expression of FASLG mRNA]; SB 203580 affects the reaction [temozolomide results in increased expression of FASLG mRNA] |
CTD |
PMID:26418950 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fbxo32 |
F-box protein 32 |
affects response to substance |
ISO |
FBXO32 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:98,065,664...98,098,071
Ensembl chr 7:98,063,735...98,098,268
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
[temozolomide co-treated with Thalidomide] results in decreased expression of FGF2 protein |
CTD |
PMID:16327979 |
|
NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
|
|
G |
Fhl2 |
four and a half LIM domains 2 |
affects response to substance |
ISO |
FHL2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 9:49,920,611...49,994,906
Ensembl chr 9:49,920,854...49,950,093
|
|
G |
Foxf2 |
forkhead box F2 |
affects response to substance |
ISO |
FOXF2 mRNA affects the susceptibility to Temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr17:34,150,417...34,156,450
|
|
G |
Fut8 |
fucosyltransferase 8 |
affects response to substance |
ISO |
FUT8 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:100,305,957...100,537,208
Ensembl chr 6:100,337,226...100,537,224
|
|
G |
Gabra2 |
gamma-aminobutyric acid type A receptor subunit alpha 2 |
affects response to substance |
ISO |
GABRA2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr14:39,662,411...39,801,082
Ensembl chr14:39,661,968...39,798,302
|
|
G |
Galnt15 |
polypeptide N-acetylgalactosaminyltransferase 15 |
affects response to substance |
ISO |
GALNT15 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:8,127,599...8,178,101
Ensembl chr16:8,128,689...8,177,841
|
|
G |
Garnl3 |
GTPase activating Rap/RanGAP domain-like 3 |
affects response to substance |
ISO |
GARNL3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:12,034,131...12,176,591
Ensembl chr 3:12,034,413...12,155,098
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions increases expression |
ISO |
resveratrol promotes the reaction [temozolomide results in increased expression of GFAP protein]; temozolomide promotes the reaction [resveratrol results in increased expression of GFAP protein] |
CTD |
PMID:22530672 |
|
NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
|
|
G |
Glrb |
glycine receptor, beta |
affects response to substance |
ISO |
GLRB mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:179,768,040...179,842,612
Ensembl chr 2:179,769,009...179,842,547
|
|
G |
H2ax |
H2A.X variant histone |
multiple interactions decreases response to substance increases phosphorylation |
ISO |
[Temozolomide co-treated with Resveratrol] results in increased phosphorylation of H2AX protein H2AX protein results in decreased susceptibility to Temozolomide Temozolomide results in increased phosphorylation of H2AX protein |
CTD |
PMID:21555580 PMID:23522185 PMID:26418950 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hhat |
hedgehog acyltransferase |
affects response to substance |
ISO |
HHAT mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr13:111,235,325...111,489,075
Ensembl chr13:111,236,466...111,474,411
|
|
G |
Hprt1 |
hypoxanthine phosphoribosyltransferase 1 |
increases mutagenesis multiple interactions |
ISO |
temozolomide results in increased mutagenesis of HPRT1 gene MGMT protein inhibits the reaction [temozolomide results in increased mutagenesis of HPRT1 gene] |
CTD |
PMID:17116724 |
|
NCBI chr X:158,196,640...158,228,815
Ensembl chr X:158,197,149...158,228,749
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
increases response to substance multiple interactions |
ISO |
HSPA1A mutant form results in increased susceptibility to temozolomide HSPA1A mutant form results in increased susceptibility to [Quercetin co-treated with temozolomide] |
CTD |
PMID:24126416 |
|
NCBI chr20:4,875,834...4,881,751
Ensembl chr20:4,877,324...4,879,779
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases response to substance |
ISO |
HSPB1 mutant form results in increased susceptibility to [Quercetin co-treated with temozolomide] HSPB1 mutant form results in increased susceptibility to temozolomide |
CTD |
PMID:24126416 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Igf2 |
insulin-like growth factor 2 |
affects response to substance |
ISO |
IGF2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:215,828,102...215,839,081
Ensembl chr 1:215,828,102...215,846,911
|
|
G |
Il1r1 |
interleukin 1 receptor type 1 |
affects response to substance |
ISO |
IL1R1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
|
|
G |
Il24 |
interleukin 24 |
increases response to substance multiple interactions |
ISO |
IL24 protein results in increased susceptibility to temozolomide MGMT protein promotes the reaction [IL24 protein results in increased susceptibility to temozolomide] |
CTD |
PMID:19056673 |
|
NCBI chr13:47,618,451...47,623,849
Ensembl chr13:47,618,452...47,623,849
|
|
G |
Il6 |
interleukin 6 |
affects response to substance |
ISO |
IL6 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Inhba |
inhibin subunit beta A |
affects response to substance |
ISO |
INHBA mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr17:51,894,869...51,919,998
Ensembl chr17:51,898,217...51,912,496
|
|
G |
Ipo4 |
importin 4 |
affects response to substance |
ISO |
IPO4 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr15:34,304,425...34,314,552
Ensembl chr15:34,304,425...34,314,345
|
|
G |
Kcnab2 |
potassium voltage-gated channel subfamily A regulatory beta subunit 2 |
affects response to substance |
ISO |
KCNAB2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:169,570,327...169,658,875
Ensembl chr 5:169,572,517...169,658,875
|
|
G |
Krt8 |
keratin 8 |
affects response to substance |
ISO |
KRT8 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:143,596,511...143,603,745
Ensembl chr 7:143,596,511...143,603,803
|
|
G |
Lbp |
lipopolysaccharide binding protein |
affects response to substance |
ISO |
LBP mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:154,786,232...154,812,910
Ensembl chr 3:154,786,215...154,813,464
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
increases response to substance |
ISO |
LIF mRNA results in increased susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr14:84,482,652...84,500,574
Ensembl chr14:84,482,674...84,500,642
|
|
G |
Lins1 |
lines homolog 1 |
affects response to substance |
ISO |
LINS1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:127,599,647...127,625,583
Ensembl chr 1:127,604,197...127,625,577
|
|
G |
Lman1l |
lectin, mannose-binding, 1 like |
affects response to substance |
ISO |
LMAN1L mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 8:62,386,806...62,400,370
Ensembl chr 8:62,386,806...62,399,648
|
|
G |
Lmtk2 |
lemur tyrosine kinase 2 |
affects response to substance |
ISO |
LMTK2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr12:12,409,876...12,546,111
Ensembl chr12:12,409,876...12,546,111
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression multiple interactions |
ISO |
temozolomide results in increased expression of MAP1LC3B protein Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein] |
CTD |
PMID:19567134 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Masp1 |
mannan-binding lectin serine peptidase 1 |
affects response to substance |
ISO |
MASP1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr11:80,736,424...80,806,278
Ensembl chr11:80,736,576...80,803,382
|
|
G |
Mecom |
MDS1 and EVI1 complex locus |
affects response to substance |
ISO |
EVI1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:117,396,084...117,993,604
Ensembl chr 2:117,396,007...117,454,769
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases response to substance decreases activity multiple interactions affects response to substance |
ISO |
MGMT mRNA results in decreased susceptibility to temozolomide; MGMT protein results in decreased susceptibility to temozolomide; MGMT results in decreased susceptibility to temozolomide temozolomide results in decreased activity of MGMT protein [O(6)-benzyl-2'-deoxyguanosine results in decreased activity of MGMT protein] which results in increased susceptibility to temozolomide; [O(6)-benzylguanine results in decreased activity of MGMT protein] which results in increased susceptibility to temozolomide; MGMT protein affects the reaction [BCL2L1 protein affects the susceptibility to temozolomide]; MGMT protein mutant form results in decreased susceptibility to [O(6)-(4-bromothenyl)guanine co-treated with temozolomide]; MGMT protein mutant form results in decreased susceptibility to [O(6)-benzylguanine co-treated with temozolomide]; MGMT protein promotes the reaction [IL24 protein results in increased susceptibility to temozolomide]; MGMT protein results in decreased susceptibility to [O(6)-benzylguanine co-treated with temozolomide]; O(6)-(4-bromothenyl)guanine inhibits the reaction [MGMT protein results in decreased susceptibility to temozolomide] MGMT protein inhibits the reaction [temozolomide results in increased mutagenesis of HPRT1 gene] MGMT promoter modified form affects the susceptibility to temozolomide; MGMT protein affects the susceptibility to temozolomide |
CTD |
PMID:9918549 PMID:10753191 PMID:12538819 PMID:14506174 PMID:15297393 PMID:15319033 PMID:15486188 PMID:15758010 PMID:15814657 PMID:15833865 PMID:15865885 PMID:16039682 PMID:16075413 PMID:16365179 PMID:16405512 PMID:16432170 PMID:17116724 PMID:18430789 PMID:19056673 PMID:20167086 PMID:20556481 |
|
NCBI chr 1:209,237,255...209,464,189
Ensembl chr 1:209,237,233...209,464,190
|
|
G |
Mgst2 |
microsomal glutathione S-transferase 2 |
affects response to substance |
ISO |
MGST2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:140,708,396...140,727,381
Ensembl chr 2:140,708,397...140,727,281
|
|
G |
Mlh1 |
mutL homolog 1 |
affects response to substance multiple interactions |
ISO |
MLH1 protein affects the susceptibility to temozolomide [temozolomide co-treated with O(6)-benzylguanine] affects the expression of MLH1 protein |
CTD |
PMID:12967659 PMID:18430789 PMID:20980775 |
|
NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
|
|
G |
Mlph |
melanophilin |
affects response to substance |
ISO |
MLPH mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 9:98,072,965...98,108,429
Ensembl chr 9:98,073,038...98,108,433
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
ISO |
resveratrol inhibits the reaction [temozolomide results in decreased expression of MMP9 protein] |
CTD |
PMID:22530672 |
|
NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
multiple interactions decreases response to substance increases response to substance |
ISO |
methoxyamine promotes the reaction [MPG protein results in increased susceptibility to temozolomide]; MPG protein promotes the reaction [methoxyamine results in increased susceptibility to temozolomide]; MPG protein promotes the reaction [N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride results in increased susceptibility to temozolomide]; MPG protein promotes the reaction [veliparib results in increased susceptibility to temozolomide]; POLB protein inhibits the reaction [MPG protein promotes the reaction [methoxyamine results in increased susceptibility to temozolomide]] MPG affects the reaction [MSH2 results in decreased susceptibility to temozolomide] MPG protein results in decreased susceptibility to temozolomide |
CTD |
PMID:15299078 PMID:16024643 PMID:16288039 PMID:20025921 PMID:21377995 |
|
NCBI chr10:15,661,768...15,667,995
Ensembl chr10:15,661,608...15,668,022
|
|
G |
Mpst |
mercaptopyruvate sulfurtransferase |
affects response to substance |
ISO |
MPST mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:119,626,636...119,631,317
Ensembl chr 7:119,626,637...119,631,425
|
|
G |
Msh2 |
mutS homolog 2 |
decreases response to substance multiple interactions affects response to substance |
ISO |
MSH2 results in decreased susceptibility to temozolomide MPG affects the reaction [MSH2 results in decreased susceptibility to temozolomide]; MSH2 gene mutant form promotes the reaction [temozolomide results in increased mutagenesis of B4GALNT2] [temozolomide co-treated with O(6)-benzylguanine] affects the expression of MSH2 protein MSH2 protein affects the susceptibility to temozolomide |
CTD |
PMID:18430789 PMID:20025921 PMID:20980775 |
|
NCBI chr 6:11,215,951...11,274,916
Ensembl chr 6:11,215,963...11,274,932
|
|
G |
Mt2A |
metallothionein 2A |
affects response to substance |
ISO |
MT2A mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation multiple interactions |
ISO |
temozolomide results in decreased phosphorylation of MTOR protein resveratrol promotes the reaction [temozolomide results in decreased phosphorylation of MTOR protein]; TSC1 protein affects the reaction [resveratrol promotes the reaction [temozolomide results in decreased phosphorylation of MTOR protein]]; TSC1 protein affects the reaction [temozolomide results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:22530672 |
|
NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
|
|
G |
Mturn |
maturin, neural progenitor differentiation regulator homolog |
affects response to substance |
ISO |
MTURN mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:84,854,341...84,875,300
Ensembl chr 4:84,854,386...84,871,757
|
|
G |
Nbl1 |
NBL1, DAN family BMP antagonist |
affects response to substance |
ISO |
NBL1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:157,524,569...157,535,701
Ensembl chr 5:157,524,513...157,535,664
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
affects response to substance |
ISO |
NFAT5 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:38,446,059...38,533,735
Ensembl chr19:38,446,059...38,533,735
|
|
G |
Nfib |
nuclear factor I/B |
affects response to substance |
ISO |
NFIB mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:100,436,343...100,647,962
Ensembl chr 5:100,439,082...100,647,727
|
|
G |
Nfix |
nuclear factor I X |
affects response to substance |
ISO |
NFIX mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:25,818,640...25,914,777
Ensembl chr19:25,821,780...25,914,696
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions increases response to substance |
ISO |
temozolomide inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA] NFKBIA mRNA results in increased susceptibility to temozolomide |
CTD |
PMID:16365179 PMID:17638900 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nin |
ninein |
affects response to substance |
ISO |
NIN mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:92,423,412...92,527,776
Ensembl chr 6:92,433,381...92,527,711
|
|
G |
Nkd2 |
NKD inhibitor of WNT signaling pathway 2 |
affects response to substance |
ISO |
NKD2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:32,054,390...32,085,416
Ensembl chr 1:32,058,044...32,084,877
|
|
G |
Npas2 |
neuronal PAS domain protein 2 |
affects response to substance |
ISO |
NPAS2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 9:45,901,262...46,081,880
Ensembl chr 9:45,901,741...46,081,880
|
|
G |
Npl |
N-acetylneuraminate pyruvate lyase |
affects response to substance |
ISO |
NPL mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr13:70,938,073...70,981,179
Ensembl chr13:70,938,082...70,980,913
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
affects response to substance |
ISO |
NR2F1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:5,569,954...5,579,894
Ensembl chr 2:5,569,935...5,579,894
|
|
G |
P3h3 |
prolyl 3-hydroxylase 3 |
affects response to substance |
ISO |
P3H3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:157,359,331...157,375,186
Ensembl chr 4:157,359,332...157,372,861
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions decreases response to substance |
ISO |
PARP1 protein affects the susceptibility to [temozolomide co-treated with veliparib] PARP1 protein results in decreased susceptibility to temozolomide |
CTD |
PMID:19825992 PMID:21555580 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pcdhb2 |
protocadherin beta 2 |
affects response to substance |
ISO |
PCDHB2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr18:30,375,798...30,378,194
Ensembl chr18:30,375,798...30,378,194
|
|
G |
Pde5a |
phosphodiesterase 5A |
affects response to substance |
ISO |
PDE5A mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:226,899,604...227,044,916
Ensembl chr 2:226,900,619...227,041,576
|
|
G |
Pgm2 |
phosphoglucomutase 2 |
affects response to substance |
ISO |
PGM2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr14:45,829,440...45,863,883
Ensembl chr14:45,829,446...45,863,877
|
|
G |
Phc2 |
polyhomeotic homolog 2 |
affects response to substance |
ISO |
PHC2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:146,832,552...146,931,444
Ensembl chr 5:146,882,756...146,931,444
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
affects response to substance |
ISO |
PHLDA1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:54,247,460...54,249,664
Ensembl chr 7:54,247,460...54,249,664
|
|
G |
Piga |
phosphatidylinositol glycan anchor biosynthesis, class A |
multiple interactions |
EXP |
temozolomide results in increased mutagenesis of and results in decreased activity of PIGA protein |
CTD |
PMID:27931811 |
|
NCBI chr X:31,786,823...31,799,751
Ensembl chr X:31,786,194...31,799,560
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
affects response to substance |
ISO |
PIK3C3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr18:22,964,121...23,047,896
Ensembl chr18:22,964,210...23,047,895
|
|
G |
Pik3cd |
phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta |
affects response to substance |
ISO |
PIK3CD mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:166,602,053...166,628,028
Ensembl chr 5:166,602,053...166,628,028
|
|
G |
Pitpnc1 |
phosphatidylinositol transfer protein, cytoplasmic 1 |
affects response to substance |
ISO |
PITPNC1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:95,429,879...95,697,734
|
|
G |
Pkp3 |
plakophilin 3 |
affects response to substance |
ISO |
PKP3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:213,884,795...213,897,783
Ensembl chr 1:213,886,775...213,897,783
|
|
G |
Plekhg5 |
pleckstrin homology and RhoGEF domain containing G5 |
affects response to substance |
ISO |
PLEKHG5 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:169,244,778...169,288,310
Ensembl chr 5:169,244,778...169,288,309
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
TP53 protein promotes the reaction [temozolomide results in increased expression of PMAIP1 mRNA] |
CTD |
PMID:17216584 |
|
NCBI chr18:62,159,128...62,179,635
Ensembl chr18:62,174,670...62,181,102
|
|
G |
Pms1 |
PMS1 homolog 1, mismatch repair system component |
multiple interactions |
ISO |
[temozolomide co-treated with O(6)-benzylguanine] affects the expression of PMS1 protein |
CTD |
PMID:20980775 |
|
NCBI chr 9:53,120,656...53,206,520
Ensembl chr 9:53,120,656...53,206,516
|
|
G |
Pms2 |
PMS1 homolog 2, mismatch repair system component |
multiple interactions affects response to substance |
ISO |
[temozolomide co-treated with O(6)-benzylguanine] affects the expression of PMS2 protein PMS2 protein affects the susceptibility to temozolomide |
CTD |
PMID:12967659 PMID:20980775 |
|
NCBI chr12:12,714,394...12,738,654
Ensembl chr12:12,714,394...12,738,641
|
|
G |
Polb |
DNA polymerase beta |
decreases response to substance multiple interactions |
ISO |
POLB protein results in decreased susceptibility to temozolomide POLB protein inhibits the reaction [MPG protein promotes the reaction [methoxyamine results in increased susceptibility to temozolomide]] |
CTD |
PMID:16024643 PMID:21377995 |
|
NCBI chr16:74,237,001...74,260,272
Ensembl chr16:74,237,001...74,260,271
|
|
G |
Polg2 |
DNA polymerase gamma 2, accessory subunit |
affects response to substance |
ISO |
POLG2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:94,968,836...94,979,259
Ensembl chr10:94,968,836...94,979,259
|
|
G |
Popdc3 |
popeye domain containing 3 |
affects response to substance |
ISO |
POPDC3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr20:50,394,617...50,422,551
Ensembl chr20:50,394,650...50,422,560
|
|
G |
Prex1 |
phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1 |
affects response to substance |
ISO |
PREX1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:163,329,580...163,477,822
Ensembl chr 3:163,329,975...163,477,715
|
|
G |
Prkaa2 |
protein kinase AMP-activated catalytic subunit alpha 2 |
affects response to substance |
ISO |
PRKAA2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:124,568,845...124,642,569
Ensembl chr 5:124,574,079...124,642,569
|
|
G |
Prl |
prolactin |
decreases secretion |
EXP |
temozolomide results in decreased secretion of PRL protein |
CTD |
PMID:20469984 |
|
NCBI chr17:39,814,236...39,824,299
Ensembl chr17:39,814,244...39,824,299
|
|
G |
Prrx2 |
paired related homeobox 2 |
affects response to substance |
ISO |
PRRX2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:9,681,871...9,718,051
Ensembl chr 3:9,681,871...9,718,051
|
|
G |
Prss12 |
serine protease 12 |
affects response to substance |
ISO |
PRSS12 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:227,657,983...227,717,884
Ensembl chr 2:227,657,983...227,717,884
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
ISO |
temozolomide results in decreased expression of PTGS2 mRNA temozolomide inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA] |
CTD |
PMID:17638900 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Qpct |
glutaminyl-peptide cyclotransferase |
affects response to substance |
ISO |
QPCT mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:1,657,110...1,689,575
Ensembl chr 6:1,657,331...1,689,559
|
|
G |
Rab27b |
RAB27B, member RAS oncogene family |
affects response to substance |
ISO |
RAB27B mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr18:68,486,006...68,644,595
Ensembl chr18:68,488,942...68,551,558
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
[temozolomide co-treated with resveratrol] results in increased phosphorylation of RB1 protein |
CTD |
PMID:23522185 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rbm19 |
RNA binding motif protein 19 |
affects response to substance |
ISO |
RBM19 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr12:41,907,978...41,993,969
Ensembl chr12:41,907,740...41,993,957
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
decreases activity |
ISO |
temozolomide results in decreased activity of RELA protein |
CTD |
PMID:17638900 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rgcc |
regulator of cell cycle |
affects response to substance |
ISO |
RGCC mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr15:61,551,861...61,564,695
Ensembl chr15:61,551,861...61,564,695
|
|
G |
Rgp1 |
RGP1 homolog, RAB6A GEF complex partner 1 |
affects response to substance |
ISO |
RGP1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:59,080,290...59,088,777
Ensembl chr 5:59,080,765...59,088,523
|
|
G |
Rhobtb3 |
Rho-related BTB domain containing 3 |
affects response to substance |
ISO |
RHOBTB3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:2,627,655...2,683,305
Ensembl chr 2:2,627,393...2,683,116
|
|
G |
Sat1 |
spermidine/spermine N1-acetyl transferase 1 |
affects response to substance |
ISO |
SAT1 mRNA affects the susceptibility to Temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr X:43,626,480...43,629,767
Ensembl chr X:43,625,169...43,629,765
|
|
G |
Scamp5 |
secretory carrier membrane protein 5 |
affects response to substance |
ISO |
SCAMP5 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 8:62,221,820...62,266,269
Ensembl chr 8:62,220,892...62,248,017
|
|
G |
Scn8a |
sodium voltage-gated channel alpha subunit 8 |
affects response to substance |
ISO |
SCN8A mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:142,575,629...142,683,659
Ensembl chr 7:142,575,672...142,684,114
|
|
G |
Sdc1 |
syndecan 1 |
affects response to substance |
ISO |
SDC1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:33,885,576...33,908,038
Ensembl chr 6:33,885,495...33,908,016
|
|
G |
Sema3a |
semaphorin 3A |
affects response to substance |
ISO |
SEMA3A mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:18,170,375...18,545,190
Ensembl chr 4:18,178,656...18,396,035
|
|
G |
Serpinb1a |
serpin family B member 1A |
affects response to substance |
ISO |
SERPINB1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr17:32,903,089...32,911,498
Ensembl chr17:32,904,119...32,911,495
|
|
G |
Sf1 |
splicing factor 1 |
affects response to substance |
ISO |
SF1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:221,735,512...221,749,216
Ensembl chr 1:221,735,517...221,749,086
|
|
G |
Slc14a1 |
solute carrier family 14 member 1 (Kidd blood group) |
affects response to substance |
ISO |
SLC14A1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr18:74,461,064...74,504,475
Ensembl chr18:74,461,055...74,485,139
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
affects response to substance |
ISO |
SLC15A2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr11:66,932,664...66,961,708
Ensembl chr11:66,932,614...66,961,713
|
|
G |
Slc22a5 |
solute carrier family 22 member 5 |
affects response to substance |
ISO |
SLC22A5 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:39,201,101...39,228,090
Ensembl chr10:39,201,107...39,323,853
|
|
G |
Slpi |
secretory leukocyte peptidase inhibitor |
affects response to substance |
ISO |
SLPI mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:160,799,979...160,802,228
Ensembl chr 3:160,799,981...160,802,433
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions decreases expression affects response to substance |
ISO |
temozolomide inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA] temozolomide results in decreased expression of SOD2 mRNA SOD2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 PMID:17638900 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
affects response to substance |
ISO |
SOX9 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
Temozolomide promotes the reaction [TP53 protein binds to SP1 protein] |
CTD |
PMID:29164620 |
|
NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
affects response to substance |
ISO |
SPARC mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr10:40,742,390...40,764,232
Ensembl chr10:40,742,400...40,764,185
|
|
G |
Spen |
spen family transcriptional repressor |
affects response to substance |
ISO |
SPEN mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:160,015,573...160,070,915
Ensembl chr 5:160,015,454...160,070,965
|
|
G |
Sqle |
squalene epoxidase |
affects response to substance |
ISO |
SQLE mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:99,609,929...99,624,803
Ensembl chr 7:99,609,191...99,624,732
|
|
G |
St3gal1 |
ST3 beta-galactoside alpha-2,3-sialyltransferase 1 |
affects response to substance |
ISO |
ST3GAL1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:107,895,045...107,963,158
Ensembl chr 7:107,895,045...107,963,142
|
|
G |
Stc1 |
stanniocalcin 1 |
affects response to substance |
ISO |
STC1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr15:50,891,137...50,901,791
Ensembl chr15:50,891,127...50,903,162
|
|
G |
Stxbp6 |
syntaxin binding protein 6 |
affects response to substance |
ISO |
STXBP6 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 6:65,086,483...65,319,527
Ensembl chr 6:65,089,318...65,319,527
|
|
G |
Synpo2 |
synaptopodin 2 |
affects response to substance |
ISO |
SYNPO2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:227,255,243...227,411,924
Ensembl chr 2:227,255,902...227,411,964
|
|
G |
Tagln |
transgelin |
affects response to substance |
ISO |
TAGLN mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 8:50,222,895...50,228,369
Ensembl chr 8:50,222,896...50,231,357
|
|
G |
Tbx3 |
T-box transcription factor 3 |
affects response to substance |
ISO |
TBX3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr12:42,479,518...42,494,588
Ensembl chr12:42,480,560...42,492,526
|
|
G |
Tcim |
transcriptional and immune response regulator |
increases response to substance |
ISO |
TCIM mRNA results in increased susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:72,401,526...72,403,180
Ensembl chr16:72,401,887...72,403,179
|
|
G |
Tdrp |
testis development related protein |
affects response to substance |
ISO |
TDRP mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:80,729,342...80,755,397
Ensembl chr16:80,729,400...80,755,415
|
|
G |
Tert |
telomerase reverse transcriptase |
decreases response to substance multiple interactions |
ISO |
TERT protein mutant form results in decreased susceptibility to temozolomide 3-aminobenzamide inhibits the reaction [TERT protein mutant form results in decreased susceptibility to temozolomide] |
CTD |
PMID:12488552 |
|
NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
|
|
G |
Tfap2c |
transcription factor AP-2 gamma |
affects response to substance |
ISO |
TFAP2C mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:170,550,314...170,558,197
Ensembl chr 3:170,550,314...170,558,194
|
|
G |
Tfdp1 |
transcription factor Dp-1 |
affects response to substance |
ISO |
TFDP1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:81,088,642...81,127,244
Ensembl chr16:81,089,292...81,127,257
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
affects response to substance |
ISO |
TFPI2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:28,947,951...28,953,261
Ensembl chr 4:28,947,965...28,953,067
|
|
G |
Thbd |
thrombomodulin |
affects response to substance |
ISO |
THBD mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 3:142,748,673...142,752,325
Ensembl chr 3:142,748,674...142,752,325
|
|
G |
Tmem158 |
transmembrane protein 158 |
affects response to substance |
ISO |
TMEM158 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 8:132,344,710...132,345,708
Ensembl chr 8:132,344,710...132,345,708
|
|
G |
Tmem19 |
transmembrane protein 19 |
affects response to substance |
ISO |
TMEM19 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 7:58,316,583...58,343,761
Ensembl chr 7:58,316,514...58,343,145
|
|
G |
Tmprss15 |
transmembrane serine protease 15 |
affects response to substance |
ISO |
TMPRSS15 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr11:17,561,591...17,684,903
Ensembl chr11:17,561,596...17,684,903
|
|
G |
Tnc |
tenascin C |
affects response to substance |
ISO |
TNC mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:79,789,686...79,874,555
Ensembl chr 5:79,789,671...79,874,671
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
temozolomide inhibits the reaction [TNF protein results in increased expression of NFKBIA mRNA]; temozolomide inhibits the reaction [TNF protein results in increased expression of PTGS2 mRNA]; temozolomide inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]; temozolomide inhibits the reaction [TNF protein results in increased expression of XIAP mRNA] |
CTD |
PMID:17638900 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
increases response to substance |
ISO |
TNFAIP3 mRNA results in increased susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnfrsf19 |
TNF receptor superfamily member 19 |
affects response to substance |
ISO |
TNFRSF19 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr15:41,249,820...41,316,203
Ensembl chr15:41,246,308...41,338,284
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
affects response to substance |
ISO |
TNFSF10 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases response to substance decreases response to substance increases expression |
ISO |
[Temozolomide co-treated with O(6)-benzylguanine] results in increased expression of TP53 protein; Temozolomide promotes the reaction [TP53 protein binds to SP1 protein]; TP53 protein promotes the reaction [Temozolomide results in increased expression of PMAIP1 mRNA]; TP53 protein results in increased susceptibility to [Temozolomide co-treated with O(6)-benzylguanine] TRP53 protein affects the reaction [[temozolomide co-treated with O(6)-benzylguanine] results in increased expression of BAX protein]; TRP53 protein affects the reaction [[temozolomide co-treated with O(6)-benzylguanine] results in increased expression of CDKN1A protein]; TRP53 protein mutant form inhibits the reaction [[temozolomide co-treated with O(6)-benzylguanine] results in decreased expression of BCL2 protein]; TRP53 protein results in increased susceptibility to [temozolomide co-treated with O(6)-benzylguanine] TP53 protein results in increased susceptibility to temozolomide TP53 protein results in decreased susceptibility to temozolomide temozolomide results in increased expression of TP53 protein |
CTD |
PMID:16193384 PMID:16405512 PMID:17216584 PMID:20980775 PMID:29164620 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Tpd52l1 |
TPD52 like 1 |
affects response to substance |
ISO |
TPD52L1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:28,454,949...28,578,736
Ensembl chr 1:28,454,966...28,576,553
|
|
G |
Trim50 |
tripartite motif-containing 50 |
affects response to substance |
ISO |
TRIM50 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr12:24,348,426...24,365,467
Ensembl chr12:24,348,321...24,365,324
|
|
G |
Tsc1 |
TSC complex subunit 1 |
multiple interactions |
ISO |
TSC1 protein affects the reaction [resveratrol promotes the reaction [temozolomide results in decreased phosphorylation of MTOR protein]]; TSC1 protein affects the reaction [temozolomide results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:22530672 |
|
NCBI chr 3:7,219,955...7,269,063
Ensembl chr 3:7,237,192...7,265,145
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
affects response to substance |
ISO |
TUFM mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:197,903,582...197,907,189
Ensembl chr 1:197,903,582...197,907,189
|
|
G |
Tulp3 |
TUB like protein 3 |
affects response to substance |
ISO |
TULP3 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 4:161,636,084...161,677,807
Ensembl chr 4:161,637,892...161,658,519
|
|
G |
Vamp4 |
vesicle-associated membrane protein 4 |
affects response to substance |
ISO |
VAMP4 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr13:80,460,699...80,483,597
Ensembl chr13:80,460,694...80,483,600
|
|
G |
Vat1l |
vesicle amine transport 1-like |
affects response to substance |
ISO |
VAT1L mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:46,525,895...46,693,838
Ensembl chr19:46,525,919...46,693,838
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
[temozolomide co-treated with Thalidomide] results in decreased expression of VEGFA protein |
CTD |
PMID:16327979 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Vldlr |
very low density lipoprotein receptor |
affects response to substance |
ISO |
VLDLR mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:245,236,819...245,273,688
Ensembl chr 1:245,237,736...245,269,205
|
|
G |
Wasf2 |
WASP family member 2 |
affects response to substance |
ISO |
WASF2 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 5:151,319,382...151,385,051
Ensembl chr 5:151,343,493...151,381,238
|
|
G |
Wee1 |
WEE1 G2 checkpoint kinase |
multiple interactions increases phosphorylation |
ISO |
resveratrol inhibits the reaction [temozolomide results in increased phosphorylation of WEE1 protein] |
CTD |
PMID:23522185 |
|
NCBI chr 1:174,765,228...174,790,882
Ensembl chr 1:174,767,960...174,786,361
|
|
G |
Wfdc1 |
WAP four-disulfide core domain 1 |
affects response to substance |
ISO |
WFDC1 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr19:52,313,771...52,332,721
Ensembl chr19:52,313,795...52,332,697
|
|
G |
Wnt5a |
Wnt family member 5A |
affects response to substance |
ISO |
WNT5A mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr16:4,469,451...4,490,271
Ensembl chr16:4,469,468...4,489,860
|
|
G |
Xaf1 |
XIAP associated factor 1 |
increases response to substance increases expression multiple interactions |
ISO |
XAF1 protein results in increased susceptibility to temozolomide temozolomide results in increased expression of XAF1 protein XAF1 protein promotes the reaction [temozolomide results in decreased expression of BIRC5 protein]; XAF1 protein promotes the reaction [temozolomide results in decreased expression of XIAP protein]; XAF1 protein promotes the reaction [temozolomide results in increased phosphorylation of CHK1 protein] |
CTD |
PMID:28122345 |
|
NCBI chr10:58,860,647...58,872,782
Ensembl chr10:58,860,940...58,873,674
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions decreases expression |
ISO |
temozolomide inhibits the reaction [TNF protein results in increased expression of XIAP mRNA]; XAF1 protein promotes the reaction [temozolomide results in decreased expression of XIAP protein] temozolomide results in decreased expression of XIAP mRNA; temozolomide results in decreased expression of XIAP protein |
CTD |
PMID:17638900 PMID:28122345 |
|
NCBI chr X:128,409,425...128,455,786
Ensembl chr X:128,409,472...128,453,000
|
|
G |
Zbtb7a |
zinc finger and BTB domain containing 7a |
multiple interactions |
ISO |
temozolomide promotes the reaction [resveratrol results in decreased expression of ZBTB7A protein] |
CTD |
PMID:25875864 |
|
NCBI chr 7:11,429,266...11,446,119
Ensembl chr 7:11,432,049...11,444,786
|
|
G |
Zc3h13 |
zinc finger CCCH type containing 13 |
affects response to substance |
ISO |
ZC3H13 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr15:57,340,522...57,405,287
Ensembl chr15:57,340,579...57,405,287
|
|
G |
Zfp112 |
zinc finger protein 112 |
affects response to substance |
ISO |
ZNF112 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr 1:80,944,118...80,959,072
Ensembl chr 1:80,953,275...80,958,908
|
|
G |
Zfp655 |
zinc finger protein 655 |
affects response to substance |
ISO |
ZNF655 mRNA affects the susceptibility to temozolomide |
CTD |
PMID:16365179 |
|
NCBI chr12:11,122,779...11,146,182
Ensembl chr12:11,127,754...11,144,754
|
|